Cardiology

Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

Gregory Weiss, MD, provides an overview of the updated cardiovascular disease prevention guidelines from the European Society of Cardiology, which were released at ESC Congress 2021.

Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.

Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.

The Amulet IDE Trial is the first trial to offer a head-to-head comparison of the Amplatzer Amulet occluder from Abbot against the Watchman device from Boston Scientific for left atrial appendage occlusion.

A post hoc analysis of the TWILIGHT trial suggests the effects of ticagrelor monotherapy observed in the overall trial were consistent, irrespective of diabetes and chronic kidney disease status.

Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.

Gregory Weiss, MD, reviews and offers perspective on a study presented at ESC Congress 2021 examining the association between influenza vaccines and improved outcomes in patients with cardiovascular disease.

Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.

Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.

Despite conflicting evidence surrounding older patient populations, investigators found no age-specific treatment effects on major cardiovascular outcomes.

Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.

Investigators find that substitute salt better protects older people with a history of stroke or high blood pressure against secondary outcomes of cardiovascular events and death.

A recent study found no benefits of immediate angiography over a delayed or selective strategy with respect to the 30-day risk of death from any cause.

ENVISAGE-TAVI AF is the first trial to compare edoxaban against standard of care in patients who have atrial fibrillation and have undergone successful TAVR.

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.

The direct-acting oral anticoagulant benefitted prevention of adverse clinical events, but was associated with worse major bleeding.

A randomized trial presented at ESC Congress 2021, results of SMART-MI demonstrate use of ICMs could help improve detection of arrhythmia and improve outcomes in a patient population that would normally not be eligible for ICM implantation.

New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.

A pilot study found use of drones to deliver AEDs to patients with out-of-hospital cardiac arrest could improve response times compared to traditional emergency services.

An analysis of adherence to guideline-directed management at 1-year after ACS provides data suggesting optimal adherence could prolong event-free life expectancy by a median of 7.5 years.

A study presented at ESC 2021 details a significant rise in rates of cardiac arrests with a secondary diagnosis of opioid use in the United States from 2012-2018.

Risk for major bleeding was found to be higher in patients treated with aspirin, ticagrelor compared to aspirin alone.

Globally, 331 million women and 317 million men had hypertension in 1990, compared with 626 million women and 652 million men in 2019.

The updated transcatheter aortic valve replacement system incorporates a supra-annular valve design, with a redesigned catheter tip and 4 valve sizes.

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

With approval of the Evolut FX TAVR System announced on August 24, the Evolut TAVR Platform is now indicated for symptomatic severe aortic stenosis across all patient risk categories.

The newest indication for the anticoagulant is based on phase 3 VOYAGER PAD findings showing benefit in reduced risk of major cardiovascular events among post-revascularization patients with PAD.